Drs Ursula A. Matulonis and Joyce F. Liu discuss new therapeutics for patients with endometrial cancer, including ADCs, immunotherapy, and drugs targeting replication stress.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999850. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36291804/

Uterine Cancer https://emedicine.medscape.com/article/258148-overview

Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability https://pubmed.ncbi.nlm.nih.gov/33182707/

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

PDUFA VII: Fiscal Years 2023-2027 https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vii-fiscal-years-2023-2027

NCCN Drugs & Biologics Compendium https://www.nccn.org/docs/default-source/clinical/drugs-and-biologics-compendium-user-guide.pdf

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/37627113/

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu https://pubmed.ncbi.nlm.nih.gov/29584549/

Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma https://clinicaltrials.gov/study/NCT05256225

HER2 Amplification in p53-Mutated Endometrial Carcinomas https://pubmed.ncbi.nlm.nih.gov/36900227/

Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/33335423/

Application of NGS Molecular Classification in the Diagnosis of Endometrial Carcinoma: A Supplement to Traditional Pathological Diagnosis https://pubmed.ncbi.nlm.nih.gov/36341543/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

The Role of Immunotherapy in Advanced and Recurrent MMR Deficient and Proficient Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/36493574/

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/

Phase 3, Randomized, Open-Label Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Cancer: ENGOT-en9/LEAP-001 https://pubmed.ncbi.nlm.nih.gov/34799418/

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/

FDA Grants Accelerated Approval to Fam-trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2